Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novogen, the registered owner of the European patent pertaining to the use of isoflavone phyto-oestrogen extracts of soy or clover, has reached an agreement with Laboratorios Casen-Fleet for a license in Spain to the Novogen patent.
Subscribe to our email newsletter
Laboratorios Casen-Fleet, the Spanish affiliate of the US healthcare company Fleet Laboratories, has recently acquired the red clover isoflavone-based menopause product Fitogyn from Laboratorios Gynea.
In conjunction with the product acquisition Laboratorios Casen-Fleet and Novogen have agreed on confidential terms for a patent license agreement.
Novogen’s patented dietary supplement products are Promensil, for women’s health including the relief of menopausal symptoms, and Trinovin, for prostate health. These brands are marketed directly by Novogen in Australia, Canada and the UK, and under license to distributors in the US, Europe, south east Asia and South Africa.
Christopher Naughton, CEO of Novogen, said: “Novogen was dedicated to the development of isoflavonoid technology, protected by intellectual property, in both the dietary supplement and prescription pharmaceutical arenas. In Europe Novogen has negotiated patent license agreements with Laboratorios Casen-Fleet and Melbrosin International.”